Trianni, Inc. ("TRIANNI") announced today that the Japan Patent Office granted 
the patent for TRIANNI's leading technology, The Trianni Mouse(TM). The Trianni 
Mouse is a transgenic mouse R&D platform for the discovery of fully-human 
monoclonal antibodies. 

Logo - https://mma.prnewswire.com/media/468426/Trianni_Logo.jpg 

"This patent is an important addition to our intellectual property portfolio, 
providing protection to our proprietary technology in Japan's diverse market," 
remarked Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "The issuance 
recognizes TRIANNI's unique approach of using chemically synthesized large DNA 
fragments with sequences non-existent in nature over traditional methods. 
Designed in silico, these fragments are modified versions of the mouse 
immunoglobulin loci, with human exons embedded in mouse control regions and 
intergenic DNA."

About Trianni, Inc.

Trianni, Inc. is a privately held biotech company specializing in antibody 
discovery technology. TRIANNI's lead technology, The Trianni Mouse(TM), is a 
simple-to-use platform that enables efficient generation of fully-human 
monoclonal antibodies with no developability issues. The transgenic platform 
leverages a novel approach to design, which was made possible by advances in 
DNA synthesis and genomic modification technology.  The company is 
headquartered in San Francisco, CA, USA. Additional information about TRIANNI 
is available through its corporate website, www.trianni.com.

Contact- Trianni, Inc. 
Mandy Boyd 
Director of Marketing 
1.415.231.0256 [o]
1.866.674.9314 
mandy.boyd@trianni.com  

SOURCE Trianni, Inc.